Evaluation of the survival of bacterial contaminants in an inhalable insulin powder.
Survival and growth of three model test bacterial species (Pseudomonas fluorescens, Staphylococcus epidermidis and Bacillus subtilis), present in the air and/or in the human respiratory tract, were tested in inhalable insulin-lactose powder under optimal relative humidity and temperature conditions (RH = 96% and optimal growth temperature for each bacterium of 26-37 degrees C) as well as representative indoor conditions (RH = 43% and T = 20 degrees C). The bacteria survived from 12 h to 7 days depending on the bacterial species and the test condition. P. fluorescens vegetative cells had the lowest and B. subtilis spores the highest survival rate. It was found that insulin-lactose powder does not support bacterial growth and that higher bacterial survival rate was found under representative indoor conditions. Selected experiments were performed with B. subtilis by adding sterile saliva into insulin-lactose powder to represent a typical condition for inhaler use. Furthermore, two other powders were tested with B. subtilis: one representing an inert powder without any nutrients (glass beads) and the other representing a powder with optimal nutrients (tryptic soy broth powder). The data indicate that the survival rate of B. subtilis did not change after the saliva was added and that the survival in insulin-lactose powder was similar to that in inert powder but lower than in powder with optimal nutrients. These results suggest that bacterial growth on residual powder in the inhaler under patient use conditions is unlikely and therefore the concern for patient safety is remote.
Center for Health-Related Aerosol Studies, Department of Environmental Health, University of Cincinnati, Cincinti, Ohio 45267, USA.
Atin
A
Adhikari
Tiina
T
Reponen
Sergey A
SA
Grinshpun
Rafał
R
Górny
Paul M
PM
Kovach
William L
WL
Muth
Ronald K
RK
Wolff
D000280:Administration, Inhalation; D001412:Bacillus subtilis / Q000254:growth & development; D004340:Drug Contamination; D006801:Humans; D007328:Insulin / Q000008:administration & dosage*; D009330:Nebulizers and Vaporizers / Q000382:microbiology*; D011551:Pseudomonas fluorescens / Q000254:growth & development; D013212:Staphylococcus epidermidis / Q000254:growth & development
D007328:Insulin